Mymetics Corp. is a biotechnology company, which engages in the research and development of virosome based vaccines. It focuses on next generation vaccines for infectious and life disabling diseases. The company was founded in July 1994 and is headquartered in Epalinges, Switzerland.
Company profile
Ticker
MYMX
Exchange
Website
CEO
Ronald Hugo Gerard Kempers
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Exelixis • Acorda Therapeutics ...
Former names
ICHOR CORP, PDG REMEDIATION INC
SEC CIK
Corporate docs
IRS number
251741849
MYMX stock data
Latest filings (excl ownership)
10-Q
2023 Q2
Quarterly report
18 Aug 23
NT 10-Q
Notice of late quarterly filing
15 Aug 23
8-K
Other Events
31 Jul 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
11 Apr 23
NT 10-K
Notice of late annual filing
3 Apr 23
8-K
Other Events
27 Feb 23
8-K
Other Events
8 Feb 23
8-K
Departure of Directors or Certain Officers
17 Jan 23
8-K
Departure of Directors or Certain Officers
28 Dec 22
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 402.00 k | 402.00 k | 402.00 k | 402.00 k | 402.00 k | 402.00 k |
| Cash burn (monthly) | (no burn) | (no burn) | 2.56 mm | 983.17 k | 201.33 k | 162.08 k |
| Cash used (since last report) | n/a | n/a | 7.21 mm | 2.77 mm | 566.38 k | 455.96 k |
| Cash remaining | n/a | n/a | -6.80 mm | -2.36 mm | -164.38 k | -53.96 k |
| Runway (months of cash) | n/a | n/a | -2.7 | -2.4 | -0.8 | -0.3 |